Conversion of Urine Protein-Creatinine Ratio or Urine Dipstick Protein to Urine Albumin-Creatinine Ratio for Use in Chronic Kidney Disease Screening and Prognosis: An Individual Participant–Based Meta-analysis

Keiichi Sumida, Girish N. Nadkarni, Morgan E. Grams* (Corresponding Author), Yingying Sang, Shoshana H. Ballew, Josef Coresh* (Corresponding Author), Kunihiro Matsushita, Aditya Surapaneni, Nigel Brunskill, Steven J. Chadban, Alex R. Chang, Massimo Cirillo, Kenn B. Daratha, Ron T. Gansevoort, Amit X. Garg, Licia Iacoviello, Takamasa Kayama, Tsuneo Konta, Csaba P. Kovesdy, James LashBrian J. Lee, Rupert Major, Marie Metzger, Katsuyuki Miura, David M.J. Naimark, Robert G. Nelson, Simon Sawhney, Nikita Stempniewicz, Mila Tang, Raymond R. Townsend, Jamie P. Traynor, Jose M. Valdivielso, Jack Wetzels, Kevan R. Polkinghorne, Hiddo J.L. Heerspink, the Chronic Kidney Disease Prognosis Consortium

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Although measuring albuminuria is the preferred method for defining and staging chronic kidney disease (CKD), total urine protein or dipstick protein is often measured instead.

OBJECTIVE: To develop equations for converting urine protein-creatinine ratio (PCR) and dipstick protein to urine albumin-creatinine ratio (ACR) and to test their diagnostic accuracy in CKD screening and staging.

DESIGN: Individual participant-based meta-analysis.

SETTING: 12 research and 21 clinical cohorts.

PARTICIPANTS: 919 383 adults with same-day measures of ACR and PCR or dipstick protein.

MEASUREMENTS: Equations to convert urine PCR and dipstick protein to ACR were developed and tested for purposes of CKD screening (ACR ≥30 mg/g) and staging (stage A2: ACR of 30 to 299 mg/g; stage A3: ACR ≥300 mg/g).

RESULTS: Median ACR was 14 mg/g (25th to 75th percentile of cohorts, 5 to 25 mg/g). The association between PCR and ACR was inconsistent for PCR values less than 50 mg/g. For higher PCR values, the PCR conversion equations demonstrated moderate sensitivity (91%, 75%, and 87%) and specificity (87%, 89%, and 98%) for screening (ACR >30 mg/g) and classification into stages A2 and A3, respectively. Urine dipstick categories of trace or greater, trace to +, and ++ for screening for ACR values greater than 30 mg/g and classification into stages A2 and A3, respectively, had moderate sensitivity (62%, 36%, and 78%) and high specificity (88%, 88%, and 98%). For individual risk prediction, the estimated 2-year 4-variable kidney failure risk equation using predicted ACR from PCR had discrimination similar to that of using observed ACR.

LIMITATION: Diverse methods of ACR and PCR quantification were used; measurements were not always performed in the same urine sample.

CONCLUSION: Urine ACR is the preferred measure of albuminuria; however, if ACR is not available, predicted ACR from PCR or urine dipstick protein may help in CKD screening, staging, and prognosis.

PRIMARY FUNDING SOURCE: National Institute of Diabetes and Digestive and Kidney Diseases and National Kidney Foundation.

Original languageEnglish
Pages (from-to)426-435
Number of pages13
JournalAnnals of Internal Medicine
Volume173
Issue number6
Early online date14 Jul 2020
DOIs
Publication statusPublished - 15 Sep 2020

Fingerprint Dive into the research topics of 'Conversion of Urine Protein-Creatinine Ratio or Urine Dipstick Protein to Urine Albumin-Creatinine Ratio for Use in Chronic Kidney Disease Screening and Prognosis: An Individual Participant–Based Meta-analysis'. Together they form a unique fingerprint.

  • Cite this

    Sumida, K., Nadkarni, G. N., Grams, M. E., Sang, Y., Ballew, S. H., Coresh, J., Matsushita, K., Surapaneni, A., Brunskill, N., Chadban, S. J., Chang, A. R., Cirillo, M., Daratha, K. B., Gansevoort, R. T., Garg, A. X., Iacoviello, L., Kayama, T., Konta, T., Kovesdy, C. P., ... the Chronic Kidney Disease Prognosis Consortium (2020). Conversion of Urine Protein-Creatinine Ratio or Urine Dipstick Protein to Urine Albumin-Creatinine Ratio for Use in Chronic Kidney Disease Screening and Prognosis: An Individual Participant–Based Meta-analysis. Annals of Internal Medicine, 173(6), 426-435. https://doi.org/10.7326/M20-0529